FLT4 and neoplasm: In the current study, we employed anlotinib, a multi-target tyrosine kinase inhibitor (TKI) with anti-lymphangiogenesis ability,35 and SAR131675, a selective VEGFR-3 TKI with potent anti-lymphangiogenesis activity,36 to demonstrate that the anti-lymphangiogenesis strategy can augment the accumulation of nanoparticles, macromolecules, and free drugs in tumor tissue (Fig. 1).